Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

UX016

Other · developed by Ultragenyx Pharmaceutical

Phase 1/2 Most advanced trial
RARE Developer
1 Registered trials

What is UX016?

UX016 is a drug studied in GNE myopathy, also known as distal myopathy, Nonaka type.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Musculoskeletal
Developer
Ultragenyx Pharmaceutical Inc (RARE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07511556 Phase 1/2 GNE Myopathy Recruiting RARE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

GNE Myopathy

More from Ultragenyx Pharmaceutical

Follow RARE, the company behind UX016

See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RARE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.